1. A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load. (28th October 2021) Authors: Dougan, Michael; Azizad, Masoud; Mocherla, Bharat; Gottlieb, Robert L; Chen, Peter; Hebert, Corey; Perry, Russell; Boscia, Joseph; Heller, Barry; Morris, Jason; Crystal, Chad; Igbinadolor, Awawu; Huhn, Gregory; Cardona, Jose; Shawa, Imad; Kumar, Princy; Blomkalns, Andra; Adams, Andrew C; Van Naar... Journal: Clinical infectious diseases Issue: Volume 75:Number 1(2022) Page Start: e440 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial. (7th April 2022) Authors: Chen, Peter; Behre, Gerhard; Hebert, Corey; Kumar, Princy; Farmer Macpherson, Lisa; Graham-Clarke, Peita Louise; De La Torre, Inmaculada; Nichols, Russell M; Hufford, Matthew M; Patel, Dipak R; Naegeli, April N Journal: Open forum infectious diseases Issue: Volume 9:Number 5(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗